Title : Combination of AKT inhibitor ARQ 092 and sorafenib potentiates inhibition of tumor progression in cirrhotic rat model of hepatocellular carcinoma.

Pub. Date : 2018 Feb 16

PMID : 29541403






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The AKT pathway is activated in almost half of HCC cases and in addition, long term exposure to conventional drug treatment of HCC, sorafenib, often results in over-activation of AKT, leading to HCC resistance. Sorafenib AKT serine/threonine kinase 1 Rattus norvegicus
2 The AKT pathway is activated in almost half of HCC cases and in addition, long term exposure to conventional drug treatment of HCC, sorafenib, often results in over-activation of AKT, leading to HCC resistance. Sorafenib AKT serine/threonine kinase 1 Rattus norvegicus